# PRODUCT DATA SHEET



# **Bioworld Technology CO., Ltd.**

# ACVRL1 (F231) Peptide

Cat No.: BS2555P

# **Background**

Mutations in two genes, Endoglin (also designated CD105) and ACVRL1 (activin receptorlike kinase 1, also designated TGF $\beta$  superfamily RI), are responsible for HHT. Endoglin is mutated in HHT1, and ALK-1 is mutated in HHT2, both of which are thought to be caused by haploinsufficiency. Endoglin and ALK-1 are type III and type I members of the TGF $\beta$  receptor superfamily, respectively, that are expressed on vascular endothelial cells. Endoglin can only bind ligands of the TGF $\beta$  superfamily via association with the respective ligand binding receptors for TGF $\beta$ 1, TGF $\beta$ 3, Activin-A, BMP-2 and BMP-7. ALK-1 preferentially binds TGF $\beta$ 1 and is expressed in bone marrow stromal cells, lung, brain, kidney and spleen.

#### **Swiss-Prot**

P37023

# **Applications**

**Blocking** 

# **Specificity**

This peptide can be used with studies using BS2555 ACVRL1 (F231) pAb.

# **Purification & Purity**

Synthetic peptide ACVRL1 (F231). (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### **Product**

1 mg/ml in DI water.

#### **Storage & Stability**

Store at  $4\,\mathrm{C}$  short term. Aliquot and store at  $-20\,\mathrm{C}$  long term. Avoid freeze-thaw cycles.

#### **Research Use**

For research use only, not for use in diagnostic procedure.